MNPR - NASDAQ
Monopar Therapeutics Inc.
$60.56
-1.1%Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
At a Glance
Live SnapshotMonopar Therapeutics Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Monopar Therapeutics Inc. Balance Sheet
MNPR • NASDAQ
| Monopar Therapeutics Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||||
CURRENT ASSETS | |||||||||||
61.8B | 45.8M | 7.3M | 8.2M | 20.3M | 16.7M | 13.2M | 6.9M | 9M | 2.1M | 2M | |
78.6M | 14.4M | 0.0 | 4.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
61.8B | 60.2M | 7.3M | 13.1M | 20.3M | 16.7M | 13.2M | 6.9M | 9M | 2.1M | 2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 425.2K | 149.3K | 22.6K | 22.9K | |
78.6B | 78.9K | 66.4K | 46K | 217.7K | 62.7K | 15.7K | 0.0 | 0.0 | 0.0 | 0.0 | |
140.5B | 60.3M | 7.3M | 13.2M | 20.5M | 16.8M | 13.2M | 7.3M | 9.1M | 2.1M | 2M | |
NON-CURRENT ASSETS | |||||||||||
254.9M | 0.0 | 12.6K | 61.2K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 730.6M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 730.6M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 800.4K | 800K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 68.9K | 122.4K | 410.7K | -729.8M | 0.0 | 0.0 | |
254.9M | 0.0 | 12.6K | 61.2K | 0.0 | 68.9K | 122.4K | 410.7K | 800K | 800.4K | 800K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -410.7K | 0.0 | 0.0 | 0.0 | |
140.7B | 60.3M | 7.3M | 13.2M | 20.5M | 16.9M | 13.4M | 7.3M | 9.9M | 2.9M | 2.8M | |
LIABILITIES | |||||||||||
CURRENT LIABILITIES | |||||||||||
2.7M | 2.3M | 1.8M | 3.1M | 1.6M | 1.2M | 724.2K | 399.6K | 311.9K | 64.5K | 73.8K | |
2.7M | 2.3M | 1.8M | 3.1M | 1.6M | 1.2M | 724.2K | 399.6K | 311.9K | 64.5K | 73.8K | |
0.0 | 3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.7B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.7B | 5.3M | 1.8M | 3.1M | 1.6M | 1.2M | 724.2K | 399.6K | 311.9K | 64.5K | 73.8K | |
NON-CURRENT LIABILITIES | |||||||||||
154.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
154.9M | 0.0 | 0.0 | 8.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 8.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.9B | 5.3M | 1.8M | 3.1M | 1.6M | 1.2M | 724.2K | 399.6K | 311.9K | 64.5K | 73.8K | |
SHAREHOLDERS' EQUITY | |||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 116.0 | 112.0 | |
6.7M | 6.1K | 14.9K | 12.9K | 12.6K | 11.5K | 10.6K | 9.3K | 9.3K | 0.0 | 0.0 | |
227.2M | 130.8M | 65.8M | 61.9M | 60.2M | 47.9M | 38.5M | 28.6M | 28M | 4.7M | 3.4M | |
-89.5B | -75.8M | -60.2M | -51.8M | -41.3M | -32.2M | -25.9M | -21.7M | -18.4M | -1.9M | -687.3K | |
131.4M | 36K | -14.1K | 8.9K | -3.2K | -7.9K | -11K | -2.4K | 0.0 | 0.0 | 0.0 | |
227.2B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
137.8B | 55M | 5.6M | 10.1M | 18.9M | 15.7M | 12.6M | 6.9M | 9.6M | 2.8M | 2.8M | |
137.8B | 55M | 5.6M | 10.1M | 18.9M | 15.7M | 12.6M | 6.9M | 9.6M | 2.8M | 2.8M | |
SUMMARY | |||||||||||
140.7B | 60.3M | 7.3M | 13.2M | 20.5M | 16.9M | 13.4M | 7.3M | 9.9M | 2.9M | 2.8M | |
78.6M | 14.4M | 0.0 | 4.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 800.4K | 800K | |
154.9M | 0.0 | 0.0 | 8.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-61.7B | -45.8M | -7.3M | -8.2M | -20.3M | -16.7M | -13.2M | -6.9M | -9M | -2.1M | -2M | |
6,169,961 | 6,169,961 | 6,169,961 | 6,169,961 | 6,169,961 | 6,169,961 | 6,169,961 | 6,169,961 | 6,169,961 | 6,169,961 | 6,169,961 |
SEC Filings
MNPR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 20, 2026 | April 19, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 01, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 |
Related Guides
Continue your MNPR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.